MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritisJanneke Anink, Dirk Holzinger, Lisette W. A. van Suijlekom‐Smit et al.|Arthritis Research & Therapy|2015Cited by 81
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Joost F. Swart et al.|Annals of the Rheumatic Diseases|2012Cited by 59
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Janneke Anink et al.|Annals of the Rheumatic Diseases|2014Cited by 58
Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Lisette W. A. van Suijlekom‐Smit, Femke H. M. Prince et al.|Lara D. Veeken|2015Cited by 52
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Lisette W. A. van Suijlekom‐Smit, M.H. Otten et al.|Lara D. Veeken|2013Cited by 40